Brexit ‘will put UK access to cutting-edge medicines at risk’

Letter from top drugs companies offers boost to David Cameron and remain campaign in EU referendum

British people benefit at the earliest opportunity from the best medicines produced by "cutting-edge" research because the UK is part of the EU, 93 business leaders and organisations from the life-sciences industry say.

The group, which includes executives from the top trio of companies - GlaxoSmithKline, AstraZeneca and Pfizer - says EU funding for research and Europe-wide regulations help produce new, more effective drugs more quickly.

Continue reading...